The Network has been instrumental in building an infrastructure prompting several of the above-mentioned EU-funded projects:
- ADDUCE (Attention-Deficit Hyperactivity Disorder Drugs Use Chronic Effects, www.adhd-adduce.org)
- TACTICS (The “Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes”, www.tactics-project.eu)
- AGGRESSOTYPE (“Aggression Subtyping for Improved Insight and Treatment Innovation in Psychiatric Disorders”, www.aggressotype.eu)
- MATRICS (“Multidisciplinary Approaches to Translational Research In Conduct Syndromes”, www.matrics-project.eu)
Other projects have been submitted to the Ho2020 program in October 2014:
- APPLE, Antipsychotics in the paediatric population: limiting exposure (CIMH, UNIDUN, RUNMC, UNICA, CIBERSAN, and others). Failed.
- OPTI-MED, Establishing optimal ADHD medication strategies across Europe (UMGC, UNIDUN, UNIDRE, UNICA and others). Failed.
- TAPS Treatment of ADHD in pre-schoolers (UNIDUN,RUNMC, UNICA and others). Failed.
- NIOTAS Neuroimmune Interactions in ObsessiveCompulsive, Tourette’s, AttentionDeficit/ Hyperactivity and Autism Spectrum Disorders (UNIDUN, UMCG, UNICA, UCBM and others). Failed.
- NIOTAS Neuroimmune Interactions in ObsessiveCompulsive, Tourette's, AttentionDeficit/Hyperactivity and Autism Spectrum Disorders (UNIDUN, UMCG, UNICA, UCBM and others). Failed.
- COBRA, COmputational approaches for Biomarker Identification in Attention Deficit HypeRActivity Disorder (ADHD) (UNIDUN, RUNMC, CIMH, UCBM, UNICA, and others). Failed after passing to second stage.
Unmet needs in pediatric psychopharmacology: present scenario and future perspectives. AM Persico, C Arango, JK Buitelaar, CU Correll, JC Glennon, PJ Hoekstra, C Moreno, B Vitiello, J Vorstman, A Zuddas, and the European Child and Adolescent Clinical Psychopharmacology Network. European Neuropsychopharmacology (2015), in press (http://dx.doi.org/10.1016/j.euroneuro.2015.06.009). Highlights of the article:
- The off-label prescription to children and adolescents of medications with regulatory approval only in adults
- The lack of effective drugs for many childhood disorders
- In search for evidence-based approaches to prevent mental disorders with adolescent-onset
- The need for better preclinical data to foster novel drug therapies
- Paediatric clinical trials: methodological issues, problems and potential solutions
- The regulatory context of paediatric psychopharmacology in Europe: strengths and limitations
- The potential limit set by categorical psychiatric nosology on paediatric drug development
- Limited public acceptance of treating children with medications
- European collaborative efforts and future directions